|
[1] Ostapowicz G, Fontana RJ, Schiodt FV, et al.Results of a pro-spective study of acute liver failure at 17 tertiary care centers in theUnited States[J].Ann Intern Med, 2002, 137 (12) :947-954.
|
|
[2]Larrey D.Epidemiology and individual susceptibility to adverse drugreactions affecting the liver[J].Semin Liver Dis, 2002, 22 (2) :145-155.
|
|
[3]Lee WM, Squires RH Jr, Nyberg SL, et al.Acute liver failure:Summary of a workshop[J].Hepatology, 2008, 47 (4) :1401-1415.
|
|
[4]Lucena MI, Andrade RJ, Kaplowitz N, et al.Phenotypic characteriza-tion of idiosyncratic drug-induced liver injury:the influence of ageand sex[J].Hepatology, 2009, 49 (6) :2001-2009.
|
|
[5]Myers RP, Shaheen AA, Li B, et al.Impact of liver disease, alco-hol abuse, and unintentional ingestions on the outcomes of acet-aminophen overdose[J].Clin Gastroenterol Hepatol, 2008, 6 (8) :918-925.
|
|
[6]Lammert C, Einarsson S, Saha C, et al.Relationship between dailydose of oral medications and idiosyncratic drug-induced liver inju-ry:search for signals[J].Hepatology, 2008, 47 (6) :2003-2009.
|
|
[7]Daly AK, Donaldson PT, Bhatnagar P, et al.HLA-B*5701 genotypeis a major determinant of drug-induced liver injury due to flucloxacil-lin[J].Nat Genet, 2009, 41 (7) :816-819.
|
|
[8]Daly AK, Day CP.Genetic association studies in drug-induced liverinjury[J].Semin Liver Dis, 2009, 29 (4) :400-411.
|
|
[9]Navarro V.Hepatic adverse event nomenclature document (online) .Available from URL:http://www.fda.gov/cder/livertox/presenta-tions 2005/vic-Navarro.ppt. (accessed 5 February 2009)
|
|
[10]Andrade RJ, Lucena MI, Kaplowitz N, et al.Outcome of acute idi-osyncratic drug-induced liver injury:Long-term follow-up in ahepatotoxicity registry[J].Hepatology, 2006, 44 (6) :1581-1588.
|
|
[11]Polson J, Lee WM.AASLD position paper:the management of acuteliver failure[J].Hepatology, 2005, 41 (5) :1179-1197.
|
|
[12]Chalasani N, Fontana RJ, Bonkovsky HL, et al.Causes, clinical fea-tures, and outcomes from a prospective study of drug-induced liver in-jury in the United States[J].Gastroenterology, 2008, 135 (6) :1924-1934.
|
|
[13]Verma S, Kaplowitz N.Diagnosis, management and prevention ofdrug-induced liver injury[J].Gut, 2009, 58 (11) :1555-1564.
|
|
[14]Danan G, Benichou C.Causality assessment of adverse reactions todrugs IA novel method based on the conclusions of international con-sensus meetings:application to drug-induced liver injuries[J].JClin Epidemiol, 1993, 46 (11) :1323-1330.
|
|
[15]Maria VA, Victorino RM.Development and validation of a clinicalscale for the diagnosis of drug-induced hepatitis[J].Hepatology, 1997, 26 (3) :664-669.
|
|
[16]Lucena MI, Camargo R, Andrade RJ, et al.Comparison of twoclinical scales for causality assessment in hepatotoxicity[J].Hepa-tology, 2001, 33 (1) :123-130.
|
|
[17]Rochon J, Protiva P, Seeff LB, et al.Reliability of the RousselUclaf Causality Assessment Method for assessing causality in drug-induced liver injury[J].Hepatology, 2008, 48 (4) :1175-1183.
|
|
[18]García Cortés M, Stephens C, Lucena MI, et al.Causality assess-ment methods in drug induced liver injury:strengths and weaknes-ses[J].J Hepatol, 2011, 55 (3) :683-691.
|
|
[19]Hoofnagle JH.Drug-induced liver injury network (DILIN) [J].Hepatology, 2004, 40 (4) :773.
|
|
[20]Fontana RJ, Watkins PB, Bonkovsky HL, et al.Drug-Induced LiverInjury Network (DILIN) prospective study:rationale, design and con-duct[J].Drug Safe, 2009, 32 (1) :55-68.
|
|
[21]Gueant JL, Gueant-Rodriguez RM, Gastin IA, et al.Pharmacoge-netic determinants of immediate and delayed reactions of drug hyper-sensitivity[J].Curr Pharm Des, 2008, 14 (27) :2770-2777.
|
|
[22]Mallal S, Phillips E, Carosi G, et al.HLA-B*5701 screeningfor hypersensitivity to abacavir[J].N Engl J Med, 2008, 358 (6) :568-579.
|
|
[23]Davern TJ 2nd, James LP, Hinson JA, et al.Measurement of ser-um acetaminophen-protein adducts in patients with acute liver fail-ure[J].Gastroenterology, 2006, 130 (3) :687-694.
|
|
[24]Padda MS, Sanchez M, Akhtar AJ, et al.Drug-induced cholestasis[J].Hepatology, 2011, 53 (4) :1377-1387.
|
|
[25]Lee WM, Hynan LS, Rossaro L, et al.Intravenous N-acetylcys-teine improves transplant-free survival in early stage non-acet-aminophen acute liver failure[J].Gastroenterology, 2009, 137 (3) :856-864.
|
|
[26]Reuben A, Koch DG, Lee WM, et al.Drug-induced acute liverfailure:results of a U.S.multicenter, prospective study[J].Hepa-tology, 2010, 52 (6) :2065-2076.
|
DownLoad: